Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Regi ...

Second Quarter 2024 Financial Results AUG 1, 2024 Agenda INTRODUCTION AYVAKIT PERFORMANCE Kate Haviland Chief Executive Officer Philina Lee, PhD Chief Commercial Officer CORPORATE PROGRESS Christy Rossi Chief Operating Officer | --- | --- | --- | |-------|-------------------------|-------| | | | | | | | | | | | | | | Q2 2024 FINANCIAL | | | | PERFORMANCE | | | | | | | | Mike Landsittel | | | | Chief Financial Officer | | Not for promotional use 2 Forward-looking statements 3 This presentation contains forwa ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.28. This compares to loss of $2.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this cancer drug developer would post a loss of $1.64 per share when it actually produced a loss of $1.32, delivering a surprise of 19.51%. Over the last four quarters, the ...

Exhibit 99.1 Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance -- Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 -- -- Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808 -- CAMBRIDGE, Mass., August 1, 2024 – Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial resu ...

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). Expected Results of an Industry Player While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicappin ...

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 299779. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call. Blueprint Medi ...

Core Insights - Blueprint Medicines Corporation is advancing the understanding and treatment of systemic mastocytosis (SM) through multiple upcoming datasets presented at key conferences, emphasizing the real-world burden of the disease and the clinical outcomes of AYVAKIT/AYVAKYT (avapritinib) [1][2][5] Group 1: Clinical Efficacy and Safety of AYVAKIT - AYVAKIT demonstrated durable efficacy and a favorable safety profile in patients with indolent systemic mastocytosis (ISM) over a median follow-up of more than two years, with safety data consistent for approximately 10% of patients who escalated to a 50 mg daily dose [1][2] - The median overall survival (OS) for AYVAKIT in advanced SM has not been reached, with a historical median OS ranging from less than six months to about 3.5 years, and an overall response rate of 73% [3][4] - AYVAKIT showed sustained improvements in total symptom scores and quality of life, with the most common treatment-related adverse event being edema, primarily Grade 1, and a low discontinuation rate of 3% due to treatment-related adverse events [2][4] Group 2: Patient Perspectives and Disease Burden - The PRISM Survey highlighted the significant burden of systemic mastocytosis on patients' quality of life, with many reporting debilitating symptoms and impaired physical and mental health functioning [5][6] - Healthcare providers acknowledged the impact of SM, with 65% indicating it affected patients' lives "quite a bit" or "a great deal," and 58% noting that patients lost employment opportunities due to the disease [6] Group 3: Upcoming Presentations and Research - Data presentations will be made available at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 and the European Hematology Association 2024 (EHA24) Hybrid Congress, covering various aspects of AYVAKIT's safety, efficacy, and the burden of SM [7][8]

AHN, or MCL, after at least one systemic therapy. In December 2023, the European Commission approved AYVAKYT for the treatment of adult patients with indolent SM with moderate to severe symptoms inadequately controlled on symptomatic treatment. These approvals in advanced SM were supported by our ongoing Phase 1 clinical trial in advanced SM, which we refer to as our EXPLORER trial, and our ongoing Phase 2 clinical trial in advanced SM, which we refer to as our PATHFINDER trial. The FDA's approval of AYVAKI ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Fouad Namouni - President-Research & Development Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating Officer Becker Hewes - Chief Medical Officer Conference Call Participants Brad Canino - Stifel Marc Frahm - TD Cowen Laura Prendergast - R ...

First Quarter 2024 Financial Results Agenda AYVAKIT PERFORMANCE | --- | --- | --- | --- | --- | |-------|-------|-------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Q1 2024 FINANCIAL | | | | | | PERFORMANCE | | | | | | | | | | | | | | | | | | Mike Landsittel | | | | | | Chief Financial Officer | | | 2 3 INTRODUCTION Kate Haviland Chief Executive Officer THE POWERFUL MAST CELL Not for promotional use Forward-looking statements This presentation contains forward-looking statem ...